

US DoD to conduct paid pilot of CT:VQ™ ahead of FDA submission

13 January 2025

Highlights

- 4DMedical wins contract to supply CT:VQ™ scans to the United States Department of Defense (DoD) ahead of FDA submission
- New contract builds off the successful previous DoD pilot of CT LVAS™
- Displacing the one million Nuclear VQ scans performed each year in the U.S. represents a billion-dollar opportunity to provide faster, safer and more accessible healthcare

Melbourne, Australia, 13 January 2025: 4DMedical Limited (ASX: 4DX) ("4DMedical" or the "Company"), a leader in advanced respiratory imaging technology, today announces it has won a contract with the United States Department of Defense (DoD) to pilot its CT Ventilation-Perfusion (CT:VQ™) technology to assess lung health in a fixed cohort of active duty personnel.

This contract builds on the success of 4DMedical's earlier agreement with the DoD for the deployment of its CT Lung Ventilation Analysis Software (CT LVAS™) in a clinical pilot program. The new arrangement reflects the DoD's recognition of the utility and impact of 4DMedical's technology in delivering critical health insights for active military personnel. The contracted arrangement with the DoD is best characterised as a commercial pilot, involving the delivery of a fixed number of scan analysis reports on full commercial terms.

Details and scope of the contract

The DoD operates one of the largest and most comprehensive healthcare systems in the world, serving over 9.6 million active-duty service members, their families, and retirees across the Military Health System (MHS). With over 200 military hospitals and clinics globally, the MHS is tasked with providing high-quality, integrated healthcare to ensure the readiness and resilience of the U.S. Armed Forces.

Under the agreement, 4DMedical will leverage its CT:VQ™ platform to conduct assessments of lung health, on 80 active-duty personnel within the DoD. This innovative imaging solution will provide unparalleled insights into ventilation and perfusion abnormalities, assisting in the early detection and monitoring of a wide range of pulmonary conditions including COPD and chronic thromboembolic hypertension. The technology is also relevant for personnel exposed to hazardous environments during military service and potentially living with associated deployment-related lung diseases.

Significance of CT:VQ™ in clinical practice

4DMedical's CT:VQ™ technology represents a game-changing innovation in lung imaging, offering a non-invasive, highly detailed view of both ventilation and perfusion within the lungs. This advanced imaging solution offers a compelling alternative to traditional Nuclear VQ scans, providing clinicians with comparable diagnostic insights while eliminating the need for radioactive isotopes and other expensive infrastructure requirements. This capability, when released, will enable clinicians to make more precise diagnoses, thereby improving patient outcomes, increasing access to care and reducing healthcare costs.



The evaluation of CT:VQ™ with the DoD, prior to FDA clearance, reaffirms the intense interest in this game-changing technology from clinicians across the U.S., while also providing a strong foundation for further opportunities within the DoD and the VA.

4DMedical MD/CEO and Founder Andreas Fouras said:

We are honoured to receive continued interest in the use of our technology from the DoD as a new pathway to enhance lung health outcomes for military personnel. This new contract underscores the value of 4DMedical's imaging solutions in addressing the unique health challenges faced by service members. We look forward to working closely with the DoD to deliver actionable insights that contribute to the readiness and well-being of the U.S. Armed Forces.

CT:VQ™ is set to disrupt a billion dollar segment of respiratory diagnostics by displacing Nuclear VQ imaging with a technology that is faster, safer, cheaper, more convenient and more accessible. We have been working for some time, leveraging hard fought experience with existing products, to build an aggressive market adoption strategy, and this contract win with the DoD, prior to FDA clearance, is testament to that work and the clear competitive advantages of our product.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity, and more personalised care for patients.

To learn more, please visit www.4dmedical.com